Asset Details
Do you wish to reserve the book?
Innovative Chitosan‐Based Formulation for Controlled Release of Enrofloxacin: Pharmacokinetic Analysis in Rabbits
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Innovative Chitosan‐Based Formulation for Controlled Release of Enrofloxacin: Pharmacokinetic Analysis in Rabbits
Do you wish to request the book?
Innovative Chitosan‐Based Formulation for Controlled Release of Enrofloxacin: Pharmacokinetic Analysis in Rabbits
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Innovative Chitosan‐Based Formulation for Controlled Release of Enrofloxacin: Pharmacokinetic Analysis in Rabbits
2025
Overview
The present study was conducted to evaluate the pharmacokinetics (PK) of a novel triple‐layer formulation of enrofloxacin (ENR) compared to a conventional ENR formulation following subcutaneous (SC) administration in rabbits as an animal model. The triple‐layer formulation comprised chitosan and β‐glycerophosphate (β‐GP) and was cross‐linked with glutaraldehyde. The PK of the conventional ENR formulation was assessed after SC administration at a dosage of 10 mg/kg in rabbits; these results were subsequently compared with the disposition kinetics of the ENR film formulation. High‐performance liquid chromatography (HPLC) was employed to quantify ENR concentrations in plasma, and non‐compartmental analysis was utilized to calculate the PK parameters. The results indicated that the film formulation facilitated sustained drug release. The mean residence time (MRT) for ENR with the film formulation (F1) was significantly enhanced, presenting a 29‐fold increase compared to the conventional formulation (p < 0.05). Although the Cmax of the conventional ENR formulation was significantly higher than that of film F1 (by a factor of 18.5), the Tmax value for film F1 was significantly greater than that of the conventional drug, showing an increase of 5.1 times. In conclusion, the triple‐layer film demonstrated favourable characteristics for the sustained delivery of ENR, particularly exhibiting a high MRT. Consequently, the use of films as a delivery system may provide an effective strategy to extend the pharmacological activity of ENR in animals. This study develops a novel triple‐layer chitosan film for sustained enrofloxacin delivery in rabbits. The implant significantly extends drug residence time (29‐fold) and maintains therapeutic levels for 144 h, offering a promising strategy to reduce dosing frequency in veterinary practice.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Anti-Bacterial Agents - administration & dosage
/ Anti-Bacterial Agents - blood
/ Anti-Bacterial Agents - chemistry
/ Anti-Bacterial Agents - pharmacokinetics
/ Chitosan
/ Delayed-Action Preparations - chemistry
/ Delayed-Action Preparations - pharmacokinetics
/ Enrofloxacin - administration & dosage
/ Enrofloxacin - pharmacokinetics
/ Glycerol
/ Male
/ Polymers
/ rabbit
/ Rabbits
/ Toxicity
We currently cannot retrieve any items related to this title. Kindly check back at a later time.